ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2232

Cost-Effectiveness of Glucosamine, Chondroitin Sulfate, Their Combination, Celecoxib,Non-Selective Non-Steroidal Anti-Inflammatory Drugs, and Placebo in Treating Knee Osteoarthritis

Vishvas Garg1, Dennis Raisch2, Ning Yan Gu3, Matthew E Borrego3 and Daniel O. Clegg4, 1College of Pharmacy, University of New Mexico (at the time of research), Grayslake, IL, 2College of Pharmacy, University of New Mexico, Albuquerque, NM, 3University of New Mexico, Albuquerque, NM, 4Rheumatology, George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Complementary alternative medicine, Cost containment, Health outcome, Nonsteroidal antiinflammatory drugs (NSAIDs) and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Session Title: Osteoarthritis - Clinical Aspects: Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Knee osteoarthritis (KOA) affects 13.8% of the US population aged ≥26, causing significant burden-of-illness. We compared the cost-effectiveness of conventional medicines such as non-steroidal anti-inflammatory drugs (NSAIDs) and celecoxib (CXB) with complementary and alternative medicines (CAM) therapies to treat KOA from the US health care payers’ and patients’ perspectives, with 24-week, 2-year, and 10-year time-horizons. 

Methods: We constructed a Markov cohort model (10-year analysis) and a decision-tree model (24-week and 2-year analyses). All costs were obtained from the published literature (converted to 2012 USD) and included both direct and indirect health care costs of medications, drug-associated adverse events, and total knee replacement surgery. Clinical efficacies for treatment strategies were obtained from the Glucosamine/CS Arthritis Intervention Trial (GAIT). Effectiveness was measured using quality-adjusted life-years (QALYs) gained, estimated from the SF-6D data collected during GAIT. Patients were stratified into mild pain only and moderate-to-severe pain groups based on their severity of knee pain. Published literature was used to obtain the rest of the modeling parameters. Base-case results were varied in both one-way and probabilistic sensitivity analyses. 

Results: We found that, among the mild, moderate, and severe patients together (from time-horizon of 24 weeks and years 2 and 10), CAM therapies were cost-effective versus conventional medicines to treat KOA in the US, with CS being the most cost-effective treatment ($1,332 per QALY gained) and glucosamine the next most cost-effective ($ 120,367 per additional QALY gained).  However, in a 24 week time-horizon among KOA patients with mild pain CXB was also incrementally cost-effective versus CS ($49,988 per QALY gained). Among moderate-to-severe pain patients from 24-week time-horizon, the combination of glucosamine and CS was the most cost-effective ($3,279 per QALY gained). A major driver of cost-effectiveness of CAM therapies over conventional medicines in the 10 year time horizon was the lack of evidence of adverse events (AEs), compared to NSAIDS and CXB which have extensively-documented AEs. 

Conclusion: Our analysis indicates CAM therapies to be more cost-effective than conventional medicines in treating KOA, due to lack of known adverse events rates and lower drug utilization costs from CAM. Prescribers may want to consider the findings of our study; however, future research is needed regarding the long-term effectiveness and safety of CAM therapies in treating KOA


Disclosure:

V. Garg,

AbbVie,

3;

D. Raisch,
None;

N. Y. Gu,
None;

M. E. Borrego,
None;

D. O. Clegg,

GAIT trial was supported by the National Center for Complementary and Alternative Medicine and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.,

2.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-effectiveness-of-glucosamine-chondroitin-sulfate-their-combination-celecoxibnon-selective-non-steroidal-anti-inflammatory-drugs-and-placebo-in-treating-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.